文献速递区域麻醉与超声术前评估与围术期医学

抗血栓药物与区域麻醉血性穿刺风险的回顾性注册分析

Antithrombotic drugs and the risk of bloody punctures in regional anesthesia - a retrospective registry analysis.
PubMed 文献 · Reg Anesth Pain Med · 2022-08-03

基于65,814例区域麻醉的回顾性注册分析显示,服用抗血栓药物患者行外周神经阻滞时血性穿刺风险升高(校正OR 1.60),无论是否停药;而椎管内阻滞在按指南暂停药物时风险未增加(校正OR 0.95)。同时使用一种以上血小板和/或凝血级联抑制剂者风险 nearly doubled(校正OR 1.89)。

要点

  • 外周神经阻滞患者服抗血栓药时血性穿刺风险升高,停药与否均如此。
  • 椎管内阻滞按指南暂停抗血栓药后血性穿刺风险未见增加。
  • 联用多种抗血栓药物者血性穿刺风险 nearly doubled。

核心结论

  • 服抗血栓药患者行外周神经阻滞时血性穿刺风险增加, irrespective of discontinuation practice。
  • 服抗血栓药患者行椎管内阻滞时,只要按指南暂停药物,血性穿刺风险不增加。
  • 联用血小板和/或凝血级联抑制剂者风险尤其高。

研究设计与样本

  • 回顾性队列分析,纳入2007-2019年区域麻醉安全网络注册的65,814例合格区域麻醉。
  • 比较服用与未服用抗血栓药物患者的操作,主要结局为血性穿刺(穿刺过程中任何血液抽吸)。
  • 采用倾向性匹配组作为敏感性分析。

主要发现

  • 外周神经阻滞实施中,服抗血栓药者血性穿刺校正OR 1.60(95%CI 1.33至1.93;p<0.001)。
  • 椎管内阻滞中,服抗血栓药者血性穿刺校正OR 0.95(95%CI 0.82至1.10;p=0.523),前提是按指南暂停。
  • 外周和椎管内阻滞合计,联用一种以上血小板和/或凝血级联抑制剂者校正OR 1.89(95%CI 1.48至2.40;p<0.001)。

关键数值与推荐

  • 血性穿刺定义为穿刺过程中任何类型的血液抽吸。
  • 椎管内阻滞按指南暂停抗血栓药时血性穿刺风险未增加(校正OR 0.95;95%CI 0.82至1.10;p=0.523)。
  • 联用多种抗血栓药物者血性穿刺校正OR 1.89(95%CI 1.48至2.40;p<0.001)。

临床怎么用

  • 椎管内麻醉前按指南暂停抗血栓药可有效降低血性穿刺风险。
  • 外周神经阻滞即使停药,服抗血栓药者血性穿刺风险仍高,需警惕。
  • 联用多种抗血栓药物者应特别关注出血风险。
  • 椎管内麻醉的停药指南可能应扩展至高危外周神经阻滞。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The risk of bleeding during regional anesthesia implementation in patients on antithrombotic therapy remains poorly characterized. We; therefore, analyzed bloody tap rates and adjusted ORs comparing patients who take antithrombotic medications with those who do not. METHODS: 65,814 qualifying regional anesthetics (2007-2019) from the Network for Safety in Regional Anesthesia and Acute Pain Therapy registry were included in a retrospective cohort analysis. Procedures in patients who took antithrombotic drugs were compared with procedures in patients who did not. The primary outcome was bloody puncture, defined as any kind of blood aspiration during placement. Secondarily, we considered timely discontinuation of thromboprophylaxis and the impact of various drug classes. As a sensitivity analysis, we used propensity matched groups. RESULTS: Patients on antithrombotic therapy were more likely to have a bloody puncture during peripheral nerve block implementation (adjusted OR 1.60; 95% CI 1.33 to 1.93; p<0.001) irrespective of whether therapy was discontinued. In contrast, bloody neuraxial blocks were no more common in patients who took antithrombotic medications (adjusted OR 0.95; 95% CI 0.82 to 1.10; p=0.523) so long as they were paused per guideline. Across both peripheral and neuraxial blocks, concurrent use of more than one platelet and/or coagulation cascade inhibitor nearly doubled the odds (adjusted OR, 1.89; 95% CI 1.48 to 2.40; p<0.001). DISCUSSION: Patients on antithrombotic therapy receiving peripheral blocks are at increased risk for bloody punctures irrespective of discontinuation practice. Patients having neuraxial blocks are not at increased risk so long as antithrombotics are stopped per guidelines. Patients who take combined medications are at especially high risk. Guidelines for discontinuing antithrombotic treatments for neuraxial anesthesia appear to be effective and should possibly be extended to high-risk peripheral blocks.

来源:Reg Anesth Pain Med,查看原文。版权归原作者所有。

引用

  1. Kubulus C, Gürtesch CA, Wagenpfeil G, et al. Antithrombotic drugs and the risk of bloody punctures in regional anesthesia - a retrospective registry analysis. Reg Anesth Pain Med. 2022. PMID: 35922078. doi:10.1136/rapm-2022-103806

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。